Therapy for bladder cancer
Patent Information
- Application Number
- HK62026126006
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-07
- Filing Date
- 2026-07-10
- Publication Date
- 2026-10-09
- Estimated Expiration
- 2044-03-05
Abstract
Description
Abstract This invention relates to the treatment of bladder cancer. In particular, this invention relates to a composition comprising 5-ALA hexyl ester (HAL) or a pharmaceutically acceptable salt thereof, for use in a method of bladder cancer therapy, wherein the method comprises instilling the composition into a patient's bladder, and wherein the method is not a method of photodynamic therapy.
Claims
Claims:
1. A composition comprising hexyl 5-ALA ester (HAL), or a pharmaceutically acceptable salt thereof, for use in a method of therapy for bladder cancer, wherein said method comprises instillation of said composition into the bladder of a patient, and wherein said method is not a method of photodynamic therapy.
2. A composition for use as claimed in claim 1 , wherein said method is carried out at body temperature.
3. A composition for use as claimed in claim 1 or claim 2, wherein said patient is a human.
4. A composition for use as claimed in any one of the preceding claims, wherein said method of therapy is performed in the absence of photoactivating light.
5. A composition for use as claimed in claim 4, wherein said photoactivating light is white light, blue light, red light, or any combination thereof.
6. A composition for use as claimed in any one of the preceding claims, wherein said composition is instilled into the bladder of the patient through a catheter and is left in the bladder for a period of from about 10 minutes to about 3 hours.
7. A composition for use as claimed in any one of the preceding claims, wherein the concentration of HAL in the composition is in the range from 0.1 to 5% by weight based on the total weight of the composition, or the equivalent concentration of a pharmaceutically acceptable salt of HAL.
8. A composition for use as claimed in any one of the preceding claims, wherein said composition is an aqueous solution of HAL or a pharmaceutically acceptable salt thereof, preferably a solution of HAL or a pharmaceutically acceptable salt thereof in an aqueous buffer, more preferably a solution of HAL or a pharmaceutically acceptable salt thereof in a phosphate buffer.
9. A composition for use as claimed in claim 8, wherein the pH of said composition is in the range of 4.5 to 7.5, preferably in the range of 5.7 to 7.2.
10. A composition for use as claimed in any one of the preceding claims, wherein said composition is a solution of 2 mg / ml HAL hydrochloride in an aqueous buffer comprising disodium phosphate dihydrate, potassium dihydrogen phosphate, sodium chloride, hydrochloric acid, sodium hydroxide and water.
11. A composition for use as claimed in any one of the preceding claims, wherein said bladder cancer is muscular invasive bladder cancer (MIBC).
12. A composition for use as claimed in any one of claims 1 to 10, wherein said bladder cancer is non-muscular invasive bladder cancer (NMIBC).
13. A composition for use as claimed in claim 12, wherein said bladder cancer is NMIBC with a high risk of progression.
14. A composition for use as claimed in any one of the preceding claims, wherein said method of therapy is carried out in a bladder cancer patient who has undergone a transurethral resection.
15. A composition for use as claimed in any one of the preceding claims in the prevention of recurrence of said bladder cancer.
16. A composition for use as claimed in any one of claims 1 to 13, wherein said method of therapy is an adjuvant therapy, preferably wherein said bladder cancer is NMIBC and said method of therapy is carried out prior to or after a transurethral resection of NMIBC.
17. A composition for use as claimed in claim 16, wherein said bladder cancer is NMIBC and said method of therapy is carried out after a transurethral resection of NMIBC.
18. A composition for use as claimed in claim 16 or claim 17, wherein said method of therapy replaces or partially replaces other adjuvant therapies for the treatment of bladder cancer, preferably wherein said other adjuvant therapies are chemotherapy and / or immunotherapy, for example BCG treatment.
19. A composition for use as claimed in any one of claims 1 to 13, wherein said method of therapy is a neoadjuvant therapy, preferably wherein said bladder cancer is MIBC and said method of therapy is carried out prior to a cystectomy.